Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selgantolimod + nivolumab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Selgantolimod + nivolumab** is an investigational combination therapy for the treatment of chronic hepatitis B virus (HBV) infection. Selgantolimod is an oral small molecule agonist of Toll-like receptor 8 (TLR8), developed to stimulate innate immune responses and modulate antiviral immunity. Nivolumab is a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) that enhances T-cell mediated immune responses against infected or malignant cells. In combination, this regimen aims to suppress HBV antigens and restore HBV-specific immune response, moving towards a functional cure. Selgantolimod is developed by Gilead Sciences[1][2][3], while nivolumab (Opdivo) is developed and marketed by Bristol Myers Squibb. Clinical trials are underway (Phase 2) evaluating this combination (sometimes with additional agents such as VIR-2218 and tenofovir alafenamide)[2][3] for safety, tolerability, and efficacy in chronic HBV.
- Other names
- selgantolimodGS-9688GS9688GS 9688nivolumabOpdivo
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on selgantolimod + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selgantolimod + nivolumab.